For research use only. Not for therapeutic Use.
Celgosivir Hydrochloride（Cat No.:I013700）is a high-purity α-glucosidase I inhibitor widely used in antiviral and biochemical research. Derived from the natural product castanospermine, it interferes with glycoprotein processing, disrupting the maturation of viral glycoproteins essential for infectivity. Celgosivir Hydrochloride has shown promise in the treatment of flavivirus infections, including dengue and hepatitis C virus (HCV), by inhibiting viral replication. Its unique mechanism of action makes it a valuable tool for exploring antiviral strategies and understanding host-virus interactions.
| Catalog Number | I013700 |
| CAS Number | 141117-12-6 |
| Molecular Formula | C₁₂H₂₂ClNO₅ |
| Purity | ≥95% |
| Target | Anti-infection |
| Solubility | H2O: ≥ 200 mg/mL |
| IUPAC Name | [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate;hydrochloride |
| InChI | InChI=1S/C12H21NO5.ClH/c1-2-3-9(15)18-8-6-13-5-4-7(14)10(13)12(17)11(8)16;/h7-8,10-12,14,16-17H,2-6H2,1H3;1H/t7-,8-,10+,11+,12+;/m0./s1 |
| InChIKey | KXNZMBFOWDNCRU-QVMZSJACSA-N |
| SMILES | CCCC(=O)O[C@H]1CN2CC[C@@H]([C@@H]2[C@H]([C@@H]1O)O)O.Cl |
| Reference | [1]. Taylor DL, et al. Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoylcastanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrob Agents Chemother. 1994 Aug;38(8):1780-7.<br>[2]. Whitby K, et al. Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Antivir Chem Chemother. 2004 May;15(3):141-51.<br>[3]. Watanabe S, et al. Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Antiviral Res. 2012 Oct;96(1):32-5. <br>[4]. Rathore AP, et al. Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes andprotects against lethal challenge mouse model. Antiviral Res. 2011 Dec;92(3):453-60. |
